Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | DPYD | Q12882 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.35 |
| ▸ | TUBB | P07437 | 1/20 | 0.35 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL158477 | 0.72 | ALDH1A1 (0.73) | ALDH1A1KDM4ECYP1A2RAB9ABLM | |
| SCHEMBL3651174 | 0.69 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2APOLBKDM4E | |
| SCHEMBL6360069 | 0.69 | PNP (0.58) | ALDH1A1KMT2AKDM4EADORA2AHSD17B10 | |
| SCHEMBL2352519 | 0.68 | PNP (0.43) | ALDH1A1MEN1KMT2APOLBKDM4E | |
| SCHEMBL6275156 | 0.66 | PNP (0.42) | ALDH1A1MEN1KMT2APOLBKDM4E | |
| SCHEMBL10998 | 0.65 | GDA (0.53) | ALDH1A1MEN1KMT2APOLBKDM4E | |
| SCHEMBL133948 | 0.65 | PNP (0.41) | ALDH1A1MEN1KMT2APOLBKDM4E | |
| SCHEMBL9949248 | 0.65 | PNP (0.41) | ALDH1A1MEN1KMT2APOLBKDM4E | |
| SCHEMBL8356642 | 0.65 | PNP (0.41) | ALDH1A1MEN1KMT2APOLBKDM4E | |
| SCHEMBL8963953 | 0.65 | DPYD (0.42) | ALDH1A1DPYDMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6329349-B1 | CARDIOVASCULAR DISORDERS USING CARDIOPROTECTIVE AGENTS | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2001-12-11 | — | — | US | claimed |
| US-6211165-B1 | GENE EXPRESSION; BINARY CONJUGATES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2001-04-03 | — | — | US | claimed |
| CN-119139469-A | Application of adenosine receptor inhibitor in preparing medicament for treating hyperlipidemia and cardiovascular and cerebrovascular diseases | 武汉大学 | 2024-12-17 | — | — | CN | disclosed |
| US-20230017597-A1 | 8-SUBSTITUTED STYRYL XANTHINE DERIVATIVES AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| WO-2021093701-A1 | 8-SUBSTITUTED STYRYL XANTHINE DERIVATIVES AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021093701-A1 | 8-SUBSTITUTED STYRYL XANTHINE DERIVATIVES AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021093701-A1 | 8-SUBSTITUTED STYRYL XANTHINE DERIVATIVES AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-05-20 | — | — | WO | disclosed |
| CN-110041331-B | Styrylxanthine derivative and use thereof | 广东东阳光药业有限公司 | 2020-08-07 | — | — | CN | disclosed |
| CN-110041331-B | Styrylxanthine derivative and use thereof | 广东东阳光药业有限公司 | 2020-08-07 | — | — | CN | disclosed |
| CN-110041331-B | Styrylxanthine derivative and use thereof | 广东东阳光药业有限公司 | 2020-08-07 | — | — | CN | disclosed |
| WO-2020125779-A1 | 8-SUBSTITUTED STYRYL XANTHINE DERIVATIVES AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-06-25 | — | — | WO | disclosed |
| CN-110041331-A | Styryl xanthine derivative and application thereof | 广东东阳光药业有限公司 | 2019-07-23 | — | — | CN | disclosed |
| CN-110041331-A | Styryl xanthine derivative and application thereof | 广东东阳光药业有限公司 | 2019-07-23 | — | — | CN | disclosed |
| US-6586413-B2 | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-07-01 | — | — | US | disclosed |
| EP-0991414-A4 | METHODS AND COMPOSITIONS FOR REDUCING ISCHEMIC INJURY OF THE HEART BY ADMINISTERING ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS | UNIV PENNSYLVANIA (US) | 2002-10-02 | — | — | EP | disclosed |
| US-6329349-B1 | CARDIOVASCULAR DISORDERS USING CARDIOPROTECTIVE AGENTS | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2001-12-11 | — | — | US | disclosed |
| EP-0991414-A1 | METHODS AND COMPOSITIONS FOR REDUCING ISCHEMIC INJURY OF THE HEART BY ADMINISTERING ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2000-04-12 | — | — | EP | disclosed |
| WO-1999020284-A1 | METHODS FOR REDUCING ISCHEMIC INJURY OF THE HEART VIA THE SEQUENTIAL ADMINISTRATION OF MONOPHOSPHORYL LIPID A AND ADENOSINE RECEPTOR AGENTS | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1999-04-29 | — | — | WO | disclosed |
| US-5859019-A | Methods for protecting against cardiac ischemia by administering adenosine A2a receptor antagonists | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1999-01-12 | — | — | US | disclosed |
| WO-1998050047-A1 | METHODS AND COMPOSITIONS FOR REDUCING ISCHEMIC INJURY OF THE HEART BY ADMINISTERING ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230017597-A1 | 8-SUBSTITUTED STYRYL XANTHINE DERIVATIVES AND USES THEREOF | ADORA2A, ADORA3, ADORA2B | ALDH1A1 465/4885DPYD 639/4885MEN1 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.